General Considerations
The Fenclofenac Clinical Research Programme was initiated in 1974, and developed along classical lines as illustrated in Fig 1. Initial pilot studies were all conducted on an open basis and once definition of the therapeutic dose range had been achieved the first, and in many ways the most important, double-blind studies were carried out, comparing fenclofenac with placebo in chronic rheumatological conditions. While this first group of comparative studies was in progress, the ongoing open studies were further expanded on a multicentric basis, emphasis now shifting from dosage definition to the generation of long-term data on tolerance, unwanted effects and interaction patterns with concomitantly administered therapiesinformation that is fast becoming a prerequisite to the registration of a new drug in the United Kingdom, and in many overseas countries. This open multicentre study, which will shortly enter its fifth year, has also proved an excellent means of exploring the possible application of fenclofenac in various specific subacute and chronic inflammatory conditions prior to the commencement of formalized double-blind studies in these indications.
In order to facilitate handling of the vast quantity of data which was expected to accrue from the open study, patient record forms were designed in a manner which would allow ready transfer of the data to punch-cards and magnetic tapes for computer processing. The techniques involved have already been described in detail in an earlier paper (Goldberg et al. 1975) .
Following satisfactory completion of the first series of double-blind studies versus placebo, the 1 Medical Consultant to Reckitt & Colimian Pharmaceutical Division overall programme has now entered the phase of comparative studies of short and medium duration, against established agents, and studies designed to identify more precisely the influence of the compound on the rheumatoid process.
Stage 1: Definition ofTherapeutic Dose-range Since selection of the correct dosage of a new agent for the first comparative studies is integral to the success of the entire programme, considerable time and effort were devoted to this aspect of the work.
There is often a temptation in the initial stages of the clinical evaluation of a new therapeutic agent to initiate the first series of double-blind controlled studies against placebo prior to full and accurate definition of the therapeutic dose-range. This may result, at best, in the fortuitous demonstration of activity at doses which are suboptimal for the majority of patients, or, at worst, in an answer suggesting that the active agent is no better than, or even perhaps worse, than placebo. The ultimate consequence of this may be the erroneous abandonment of an acceptable and useful form of therapy. This situation was avoided in the fenclofenac project in the following way:
(1) Inclusion of as many experienced clinical investigators as possible into the open multicentre study describe above. This resulted in the admission of correspondingly large numbers of patients into the study and increased the likelihood that any conclusions drawn would be based upon a representative sample of patients suffering from chronic rheumatoid arthritis.
(2) The application of an initial dose-titration phase which enabled individualization of the dose for each patient prior to the institution of long-term maintenance therapy. This was achieved by permitting incremental increase of fenclofenac dosage by the clinician concerned when judged necessary on clinical grounds, provided that unwanted effects of a subjective nature, or untoward trends in any measured laboratory parameters, were absent. Earlier studies in healthy volunteers had demonstrated fenclofenac to have a biological half-life of 12-24 hours in man; on the basis of this finding, a twice-daily dosage regime was employed during the dosetitration phase. Data from this phase were continuously fed into the computer data-bank, and an analysis made when 173 patients had been recruited into the study. This analysis involved identification of those patients who had been satisfactorily maintained at a given dose level for an arbitrarily chosen period of two months. In this context, 'satisfactory maintenance' implied that the individual patient had demonstrated, over the period in question, an overall reduction in the following measured parameters ofdisease activity:
(1) Articular index, as measured by the method of Ritchie et al. (1968) . (2) Overall pain, using a Visual Analogue Scale as described by Berry & Huskisson (1972) . (3) Early morning stiffness.
From these data a graph was constructed to show the percentage of patients satisfactorily maintained at a given daily dosage as a function of dosage and, in addition, the percentage of patients withdrawn as a result of unwanted effects, at each dose level (Fig 2) . A possible explanation of the apparent fall-off in the percentage of patients satisfactorily maintained at the higher doses is the fact that the patients receiving these higher doses were the relatively small number who had failed to respond adequately at lower doses. It is possible that a number of these patients would not have responded to fenclofenac at any dosage.
As may be seen, the technique suggested that a dose of 900 mg daily should be satisfactory for the majority of patients, and this is the dose that was accordingly chosen for the initial comparative studies against placebo.
Full definition of the therapeutic dose range was subsequently effected by the continuous monitoring of dosage distribution as the open study progressed. At intervals throughout the study, available data were frozen and histograms constructed to indicate the percentage of patients The latest computer analysis of the data from the open multicentric study was made in August 1977, when 412 patients had entered the study. These patients were suffering from a variety of chronic rheumatological conditions as shown in Table 1 and comprised 240 females (mean age 54.9 years) and 170 males (mean age 49.9 years); in two instances sex was not recorded. The duration of therapy ranged from 0 to 33 months as shown in Table 2 .
A comparison was made between the baseline value for each clinical parameter and the latest recorded value of that parameter in those patients who had received doses within the range 600-1800 mg fenclofenac daily for any period of time.
The analysis for patients with rheumatoid arthritis is presented in Table 3 from which it may be seen that there is a statistically significant improvement (P<0.001) in all measured clinical parameters, thus providing confirmation of the conclusions drawn from Stage I that the therapeutic dose range of fenclofenac lies between 600 and 1800 mg daily. Of particular interest is the im-provement in ESR and proximal interphalangeal joint size. These parameters are objective assessments of disease activity in rheumatoid arthritis, and a reduction under the influence of therapy is generally taken to signify the presence of antiinflammatory activity in the drug substance under Table 6 Patients experiencing poor effect on anti-inflammatory/analgesic drugs used prior to fenclofenac therapy For each drug, patients experiencing poor effect have been identified and the subsequent number of withdrawals due to lack of effect on fenclofenac therapy within this group ascertained. This gives a comparison between each drug and fenclofenac in terms of efficacy and also gives information on the efficacy of fenclofenac ins a group of patients known to have experienced poor effect on other anti-inflammatory drugs I Table 7 Patients demonstrating poor tolerance to anti-inflammatory/analgesic drugs used prior to fenclofenac therapy For each drug, patients with a poor tolerance have been identified and the subsequent number of withdrawals due to side-effect on fenclofenac therapy ascertained. This gives a comparison between each drug and fenclofenac in terms of tolerance and also gives information on the tolerance of fenclofenac in a group of patients known to have tolerated previous therapies poorly investigation. The effect upon ESR was further assessed by examining those patients whose ESR had changed during the course of fenclofenac therapy. These results are presented in Table 4 . In 146 out of 198 patients (73.7 %) the ESR either remained unchanged or improved during fenclofenac therapy, and for 63 of these patients (31.8 % of the total) it was reduced by at least a half.
Data on the pain scores of patients with osteoarthrosis are presented in Table 5 . It is generally recognized that osteoarthrosis is a condition in which the inflammatory component is minimal. In this group of patients, therefore, a significant reduction in pain score is indicative of the fact that fenclofenac possesses considerable analgesic activity.
The selection criteria for admission to the study ensured that all patients admitted were either receiving anti-rheumatic therapy for the first time or were less than optimally maintained on their previous therapy. An analysis of this latter group is presented in Tables 6 and 7 from which it may be inferred that 90% of patients who were inadequately controlled by their previous therapy were adequately controlled by fenclofenac.
Similarly, 84 % of patients who were intolerant to their previous therapy tolerated fenclofenac. Thus fenclofenac is indicated for use in those patients who have shown a lack of response or poor tolerance to other anti-rheumatic agents.
Conclusions
This study demonstrates that the therapeutic dose range of fenclofenac lies between 600 and 1800 mg daily. Evidence has been adduced to show that within this dose range it possesses both anti-inflammatory and analgesic properties. By virtue of its long biological half-life, it may be administered in divided doses twice daily (or more frequently if necessary). Many patients who are unresponsive or intolerant to other anti-inflammatory agents may be adequately controlled with fenclofenac. Fenclofenac should thus prove to be a useful drug in the treatment of a wide range of rheumatological conditions.
